A Phase 4 interventional study of Golimumab and Placebo in Spondyloarthritis, sponsored by Merck Sharp & Dohme LLC. Completed at 71 sites in 9 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of treatment withdrawal compared to continued treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence of a "flare" in non-radiographic axial spondyloarthritis over up to 12 months. The primary hypothesis is that continued treatment with golimumab is superior to treatment withdrawal, based on the percentage of subjects without a "flare" during up to 12 months of blinded therapy.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
This study's enrollment of 323 is above the median of 108 across 106 interventional studies indexed under Spondylarthritis.
Browse Spondylarthritis studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets one of the following criteria:
Has active inflammation on magnetic resonance imaging (MRI) highly suggestive of sacroiliitis associated with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics:
Elevated C-reactive protein (CRP)
Has a HLA-B27+ gene and 2 or more of the following SpA characteristics:
Exclusion Criteria:
Has received any treatment listed below more recently than the indicated off-drug period prior to Screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months
Biological: Golimumab
Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months
Biological: Golimumab · Biological: Placebo
Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months
Biological: Golimumab · Biological: Placebo
Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.
Biological: Golimumab
Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
Also known as: MK-8259, Simponi®
Injections of matching placebo for golimumab.
Percentage of Participants Without a Disease Activity Flare During Period 2
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants With a Flare Who Show a Clinical Response Within 3 Months of Open-Label Golimumab Retreatment
Clinical response is defined as Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score improvement of ≥2.0 or ≥50% improvement within 3 months of the start of retreatment, relative to the mean of the two consecutive BASDAI scores that defined the flare. Sustained clinical response refers to participants who attained clinical response and maintained BASDAI criteria throughout the 3-month retreatment period. Response data was collected throughout Period 2 (12 months) and censored to include only the first 3 months after retreatment for a disease flare. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
Time frame: Up to 3 months following start of retreatment
Time to First Disease Flare
The Kaplan-Meier analysis of time to first "flare" in Period 2 is represented by the percentage of participants who experienced a disease flare relative to baseline prior to the first dose of double-blind treatment in Period 2. Disease flare is defined as ASDAS at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1.
Time frame: Month 3, Month 6, Month 9, and Month 12
Percentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment)
ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving ASAS20 Response (Open-label Retreatment)
ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving ASAS40 Response (Double-blind Treatment)
ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving ASAS40 Response (Open-label Retreatment)
ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment)
ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment)
ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Time frame: Up to 12 months
Percentage of Participants Achieving BASDAI50 Response (Double-blind Treatment)
BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of double-blind treatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants Achieving BASDAI50 Response (Open-label Retreatment)
BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of open-label retreatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment)
Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants Achieving Inactive Disease Status (Open-label Retreatment)
Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants Who Experienced an Adverse Event (AE) in Period 2
This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. The analysis includes AEs that occurred through 90 days after the last dose of study treatment.
Time frame: Up to approximately 15 months
Percentage of Participants Who Discontinued Study Treatment Due to an AE in Period 2
This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE.
Time frame: Up to approximately 12 months
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens)
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
Time frame: Up to 12 months
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen)
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
Time frame: Up to 12 months
| Milestone | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|---|
| Started | 323 | 0 | 0 | 0 | 0 |
| Completed | 207 | 0 | 0 | 0 | 0 |
| Not completed | 116 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of qualifying event | 98 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 0 | 0 | 0 | 0 |
| Milestone | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|---|
| Started | 0 | 63 | 64 | 62 | 0 |
| Completed | 0 | 53 | 43 | 21 | 0 |
| Not completed | 0 | 10 | 21 | 41 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Did not attain inactive disease in period 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Disease flare, transitioned to open-label retreatment | 0 | 10 | 15 | 38 | 0 |
| Milestone | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 63 |
| Completed | 0 | 0 | 0 | 0 | 58 |
| Not completed | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 5 |
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Without a Disease Activity Flare During Period 2 | 84.1 | 68.3 | 33.9 |
Clinical response is defined as Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score improvement of ≥2.0 or ≥50% improvement within 3 months of the start of retreatment, relative to the mean of the two consecutive BASDAI scores that defined the flare. Sustained clinical response refers to participants who attained clinical response and maintained BASDAI criteria throughout the 3-month retreatment period. Response data was collected throughout Period 2 (12 months) and censored to include only the first 3 months after retreatment for a disease flare. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Within 1 month of retreatment | 90.6 (79.3 to 96.9) |
| Within 2 months of retreatment | 96.2 (87.0 to 99.5) |
| Within 3 months of retreatment | 96.2 (87.0 to 99.5) |
| Sustained clinical response | 71.7 (57.7 to 83.2) |
The Kaplan-Meier analysis of time to first "flare" in Period 2 is represented by the percentage of participants who experienced a disease flare relative to baseline prior to the first dose of double-blind treatment in Period 2. Disease flare is defined as ASDAS at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Month 3 | 14.3 | 7.9 | 41.9 |
| Month 6 | 14.3 | 17.5 | 58.1 |
| Month 9 | 14.3 | 20.6 | 61.3 |
| Month 12 | 15.9 | 23.8 | 61.3 |
ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment) | 9.5 | 3.2 | 0.0 |
ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Percentage of Participants Achieving ASAS20 Response (Open-label Retreatment) | 94.3 (84.3 to 98.8) |
ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Achieving ASAS40 Response (Double-blind Treatment) | 0 | 0 | 0 |
ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Percentage of Participants Achieving ASAS40 Response (Open-label Retreatment) | 90.6 (79.3 to 96.9) |
ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment) | 85.7 | 85.7 | 71.0 |
ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Percentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment) | 92.5 (81.8 to 97.9) |
BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of double-blind treatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Achieving BASDAI50 Response (Double-blind Treatment) | 49.2 | 30.2 | 24.2 |
BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of open-label retreatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Percentage of Participants Achieving BASDAI50 Response (Open-label Retreatment) | 98.1 (89.9 to 100.0) |
Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) |
|---|---|---|---|
| Percentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment) | 85.7 | 84.1 | 61.3 |
Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
| Percentage of participants | Open-Label Retreatment |
|---|---|
| Percentage of Participants Achieving Inactive Disease Status (Open-label Retreatment) | 90.6 (79.3 to 96.9) |
This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. The analysis includes AEs that occurred through 90 days after the last dose of study treatment.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) in Period 2 | 46.0 | 46.9 | 32.3 | 41.3 |
This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an AE in Period 2 | 0.0 | 4.7 | 1.6 | 0.0 |
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M and Placebo (Withdrawal Regimens) |
|---|---|---|
| Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens) | 84.1 | 51.2 |
Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.
| Percentage of participants | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) |
|---|---|---|
| Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen) | 84.1 | 68.3 |
Collected over Up to 10 months in Period 1 (Open-Label Run-in) and up to 15 months in Period 2 (Withdrawal vs Continued Treatment) for a total of up to 25 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Run-In Golimumab QM | 0/323 (0%) | 7/323 (2.2%) | 79/323 (24.5%) |
| Golimumab QM (Full Treatment Regimen) | 0/63 (0%) | 1/63 (1.6%) | 13/63 (20.6%) |
| Golimumab Q2M (Reduced Treatment Regimen) | 0/64 (0%) | 1/64 (1.6%) | 17/64 (26.6%) |
| Placebo (Treatment Withdrawal Regimen) | 0/62 (0%) | 1/62 (1.6%) | 11/62 (17.7%) |
| Open-Label Retreatment | 0/63 (0%) | 0/63 (0%) | 11/63 (17.5%) |
| Event | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|---|
| Meniscus injuryInjury, poisoning and procedural complications | 0/323 | 0/63 | 0/64 | 1/62 | 0/63 |
| Joint injuryInjury, poisoning and procedural complications | 0/323 | 1/63 | 0/64 | 0/62 | 0/63 |
| Pyelonephritis acuteInfections and infestations | 0/323 | 0/63 | 1/64 | 0/62 | 0/63 |
| Renal colicRenal and urinary disorders | 1/323 | 0/63 | 1/64 | 0/62 | 0/63 |
| Cholecystitis chronicHepatobiliary disorders | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| Pilonidal cystInfections and infestations | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| Sinusitis bacterialInfections and infestations | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| ExostosisMusculoskeletal and connective tissue disorders | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| Joint instabilityMusculoskeletal and connective tissue disorders | 1/323 | 0/63 | 0/64 | 0/62 | 0/63 |
| Event | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 36/323 | 6/63 | 6/64 | 3/62 | 4/63 |
| PharyngitisInfections and infestations | 12/323 | 2/63 | 6/64 | 3/62 | 1/63 |
| Upper respiratory tract infectionInfections and infestations | 16/323 | 2/63 | 3/64 | 2/62 | 5/63 |
| HeadacheNervous system disorders | 24/323 | 4/63 | 2/64 | 4/62 | 1/63 |
| Age, Continuous(Years) | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment | Total |
|---|---|---|---|---|---|---|
| Period 1: Open-Label Run-In | 32.5 ± 7.2 | — | — | — | — | 32.5 ± 7.2 |
| Period 2: Withdrawal vs Continued Tx | — | 31.4 ± 8.0 | 30.8 ± 6.7 | 32.9 ± 6.8 | — | 31.7 ± 7.2 |
| Period 2: Open-Label Retreatment | — | — | — | — | 33.4 ± 6.7 | 33.4 ± 6.7 |
| Sex: Female, Male(Participants) | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment | Total |
|---|---|---|---|---|---|---|
| Period 1: Open-Label Run-In — Female | 109 | — | — | — | — | 109 |
| Period 1: Open-Label Run-In — Male | 214 | — | — | — | — | 214 |
| Period 2: Withdrawal vs Continued Tx — Female | — | 19 | 21 | 16 | — | 56 |
| Period 2: Withdrawal vs Continued Tx — Male | — | 44 | 43 | 46 | — | 133 |
| Period 2: Open-Label Retreatment — Female | — | — | — | — | 20 | 20 |
| Period 2: Open-Label Retreatment — Male | — | — | — | — | 43 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment | Total |
|---|---|---|---|---|---|---|
| Period 1: Open-Label Run-In — Hispanic or Latino | 2 | — | — | — | — | 2 |
| Period 1: Open-Label Run-In — Not Hispanic or Latino | 321 | — | — | — | — | 321 |
| Period 1: Open-Label Run-In — Unknown or Not Reported | 0 | — | — | — | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Hispanic or Latino | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Not Hispanic or Latino | — | 63 | 64 | 62 | — | 189 |
| Period 2: Withdrawal vs Continued Tx — Unknown or Not Reported | — | 0 | 0 | 0 | — | 0 |
| Period 2: Open-Label Retreatment — Hispanic or Latino | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — Not Hispanic or Latino | — | — | — | — | 63 | 63 |
| Period 2: Open-Label Retreatment — Unknown or Not Reported | — | — | — | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment | Total |
|---|---|---|---|---|---|---|
| Period 1: Open-Label Run-In — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 1: Open-Label Run-In — Asian | 0 | — | — | — | — | 0 |
| Period 1: Open-Label Run-In — Native Hawaiian or Other Pacific Islander | 0 | — | — | — | — | 0 |
| Period 1: Open-Label Run-In — Black or African American | 0 | — | — | — | — | 0 |
| Period 1: Open-Label Run-In — White | 323 | — | — | — | — | 323 |
| Period 1: Open-Label Run-In — More than one race | 0 | — | — | — | — | 0 |
| Period 1: Open-Label Run-In — Unknown or Not Reported | 0 | — | — | — | — | 0 |
| Period 2: Withdrawal vs Continued Tx — American Indian or Alaska Native | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Asian | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Native Hawaiian or Other Pacific Islander | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Black or African American | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — White | — | 63 | 64 | 62 | — | 189 |
| Period 2: Withdrawal vs Continued Tx — More than one race | — | 0 | 0 | 0 | — | 0 |
| Period 2: Withdrawal vs Continued Tx — Unknown or Not Reported | — | 0 | 0 | 0 | — | 0 |
| Period 2: Open-Label Retreatment — American Indian or Alaska Native | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — Asian | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — Black or African American | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — White | — | — | — | — | 63 | 63 |
| Period 2: Open-Label Retreatment — More than one race | — | — | — | — | 0 | 0 |
| Period 2: Open-Label Retreatment — Unknown or Not Reported | — | — | — | — | 0 | 0 |
| C-Reactive Protein (CRP) Category at Enrollment(Participants) | Open-Label Run-In Golimumab QM | Golimumab QM (Full Treatment Regimen) | Golimumab Q2M (Reduced Treatment Regimen) | Placebo (Treatment Withdrawal Regimen) | Open-Label Retreatment | Total |
|---|---|---|---|---|---|---|
| Period 1: Open-Label Run-In — > 6 mg/L | 196 | — | — | — | — | 196 |
| Period 1: Open-Label Run-In — ≤ 6 mg/L | 127 | — | — | — | — | 127 |
| Period 2: Withdrawal vs Continued Tx — > 6 mg/L | — | 40 | 40 | 39 | — | 119 |
| Period 2: Withdrawal vs Continued Tx — ≤ 6 mg/L | — | 23 | 24 | 23 | — | 70 |
| Period 2: Open-Label Retreatment — > 6 mg/L | — | — | — | — | 38 | 38 |
| Period 2: Open-Label Retreatment — ≤ 6 mg/L | — | — | — | — | 25 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2017 to primary completion in Mar 2021, 40 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golimumab